Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Cybin Inc
R7E1Current price
0.18 EUR
-0.01 EUR (-5.31%)
Last closed
0.22 USD
Company
www.cybin.com
ISIN
CA23256X1006
Sector
Healthcare
Industry
Biotechnology
Exchange
Frankfurt Exchange
Capitalization
194 472 688 USD
Yield for 12 month
-36.30 %
1Y
3Y
5Y
10Y
15Y
R7E1
Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in phase 1/2a clinical trial to treat major depressive disorder (MDD), as well as in preclinical trials for alcohol use disorder; CYB004, a deuterated dimethyltryptamine (DMT), which completed phase 2 clinical trial for treating generalized anxiety disorders; SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 completed phase 1, 1b, and 1/2a for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation, as well as has a research pipeline of investigational psychedelic-based compounds. The company has research and collaboration agreement with TMS Neurohealth Centers Inc. for development of psychedelic compound-based therapeutics; Kernel for use of Kernel flow technology to measure neural activity; and Greenbook TMS to establish mental health centers. The company is headquartered in Toronto, Canada. Address: 100 King Street West, Toronto, ON, Canada, M5X 1C9
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
4.29 USDP/E ratio
–Dividend Yield
–Current Year
–
Last Year
–
Current Quarter
–
Last Quarter
–
Current Year
-314 105 USD
Last Year
-185 944 USD
Current Quarter
-102 232 USD
Last Quarter
-105 196 USD
Key Figures R7E1
1 year
3 years
5 years
10 years
EBITDA
-86 204 000 USD
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-32.71 %
PEG Ratio
–
Return On Equity TTM
-49.07 %
Wall Street Target Price
4.29 USD
Revenue TTM
–
Book Value
0.37 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
–
Dividend Yield
–
Gross Profit TTM
-311 000 USD
Earnings per share
-0.15 USD
Diluted Eps TTM
-0.15 USD
Most Recent Quarter
II 2024
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics R7E1
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History R7E1
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
149:1000
Payout Ratio
–
Last Split Date
10.11.2020
Dividend Date
–
Stock Valuation R7E1
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
313.5883
Price Sales TTM
278.2498
Enterprise Value EBITDA
-3.7911
Price Book MRQ
0.9331
Financials R7E1
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators R7E1
For 52 weeks
0.23 USD
0.74 USD
50 Day MA
0.27 USD
Shares Short Prior Month
19 114 860
200 Day MA
0.35 USD
Short Ratio
2.78
Shares Short
14 903 106
Short Percent
0.5 %
BeatStart